Global investment firm The Carlyle Group is acquiring 20% in the Piramal group’s pharma business for around $490m, setting the stage for the Indian group to pursue an ambitious growth strategy including buyouts both on home turf and internationally.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?